<DOC>
	<DOCNO>NCT00012207</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining biological therapy chemotherapy may kill cancer cell . PURPOSE : Phase I trial study effectiveness biological therapy chemotherapy treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Biological Therapy After Chemotherapy Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety toxicity cellular immunotherapy autologous CD8+ cytotoxic T-lymphocyte clone chemotherapy comprise cyclophosphamide , vincristine , prednisone patient relapse refractory CD20+ indolent lymphoma mantle cell lymphoma . Secondary - Determine duration vivo persistence adoptively transfer CD20-specific CD8+ cytotoxic T-lymphocyte clone absence presence subcutaneous interleukin-2 patient . - Assess traffic CD8+ cytotoxic T-lymphocyte clone lymph nodes patient treat regimen . - Determine immune response tumor response patient treat regimen . OUTLINE : This open-label , pilot study . - Leukapheresis : Patients undergo leukapheresis . Selected CD20-specific CD8+ cell culture expand cytotoxic T lymphocyte ( CTL ) , clone . - Chemotherapy : Patients receive oral cyclophosphamide oral prednisone day 1-5 vincristine IV day 1 . Courses repeat every 3-4 week total 6 course . - Immune cell infusion : Beginning 4 week last course chemotherapy ( lymph node ≤ 5 cm diameter ≤ 5,000 circulate CD20+ lymphocytes/mm^3 ) , patient receive autologous CD8+ CTL clone IV 30 minute . Courses repeat every 2-5 day total 3 course absence disease progression unacceptable toxicity . The last 6 patient receive interleukin-2 subcutaneously every 12 hour 14 day , begin 2 hour last infusion CD8+ CTL clone . After course 2 3 immune cell , patient undergo surgical lymph node biopsy determine immune cell move lymph node . Patients follow monthly 1 year annually 2 year . PROJECTED ACCRUAL : A total 12 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Immunohistopathologically document relapsed refractory CD20+ indolent lymphoma mantle cell lymphoma Indolent Bcell lymphomas include follow subtypes : Follicular lymphoma ( grade I , II , III ) Small lymphocytic lymphoma chronic lymphocytic leukemia Marginal zone lymphoma ( splenic , nodal , extranodal ) Lymphoplasmacytoid lymphoma Ineligible unwilling participate FHCRC/UWMC protocols Serological evidence prior exposure EpsteinBarr virus Must agree undergo peripheral blood drawing , bone marrow biopsy , lymph node biopsy , nuclear medicine imaging Must agree cytoreductive chemotherapy necessary reduce lymph node &lt; 5 cm diameter circulate B lymphocyte count &lt; 5,000/mm^3 No pulmonary involvement No CNS involvement PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : At least 90 day Hematopoietic : Not specify Hepatic : No active hepatitis B infection Renal : Not specify Other : No HIV positivity Not pregnant nursing Fertile patient must use effective contraception No history hypersensitivity reaction murine protein PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 month since prior rituximab , tositumomab , ibritumomab No prior allogeneic stem cell transplantation No concurrent immunotherapy ( e.g. , interferon , vaccine , cellular product ) Chemotherapy : At least 2 year since prior fludarabine cladribine At least 4 week since prior chemotherapy recover Endocrine therapy : No concurrent systemic corticosteroid except treat toxicity chemotherapy cellular immunotherapy Radiotherapy : Not specify Surgery : Not specify Other : At least 4 week since prior immunosuppressive therapy recover No concurrent pentoxifylline No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>